Développement anticorps pour améliorer la performance du traitement contre le cancer.

  • Biotech
  • Microbiologie

Niveau de maturité

  • Idéation
  • R&D
  • Minimum viable product
  • 1er client / 1ers utilisateurs
  • Commercialisation


Cancer continues to be a leading cause of disability and early mortality worldwide. Immune checkpoint blockade with PD/L-1 therapies such as Keytruda and Opdivo can induce complete and durable clinical responses in multiple tumors, a breakthrough in cancer treatment over the last decade. However, only around 20% of patients respond and many trials have failed.

Many R&D programs in multiple companies are attempting to improve the clinical efficacy of PD/L-1 therapies, but no solution is yet approved. Most of these approaches target T-cells or the tumour microenvironment. Patients with healthier microbiomes respond better and therefore some companies are developing live biotherapeutics to enhance the microbiome, with initially promising clinical data.

Iome-Bio offers a differentiated approach through a targeted mode of action downstream of the microbiome’s action, enabling amplification of the signal with first in class monoclonal antibodies.

En savoir plus

Porteurs de projets

  • Sarah Holland

Suivez le projet

    Je souhaite m’abonner avec

    Les données personnelles recueillies par Quest for change sont utilisées afin de vous envoyer des actualités sur notre activité. Pour en savoir plus sur la gestion de vos données et droits, consultez notre politique de protection des données.